Contact us via partnering software or directly to schedule a meeting.
We will be in the area from February 11th to 14th. We are happy to meet at the seminar. One meeting slot is still open on the 14th. Contact us as soon as possible.
Neurotar’s Katja Karelina (CEO) and Leonard Khiroug (CSO) will be in Stockholm on February 7-8. One meeting slot is still available. Please contact us as soon as possible.
Investors are welcome to schedule meetings with Katja Karelina at the venue or to visit Neurotar during their stay in Helsinki. Contact Katja directly with inquiries.
Neurotar’s sales increased by a factor of 10 in 2012 compared to 2011. Sales revenues come mostly from service provision to companies located outside of Finland. Two of Neurotar’s clients are top ten pharmaceutical companies. Approximately one quarter of revenues comes from cosmetics.
Neurotar presentation in the Biomarker category focuses on the ways in which Neurotar’s services aid biomarker developers and highlights cooperation with the Swedish BioChromix AB in the area of biomarker development for Alzheimer’s.
In total, € 0,5 Mil. have been invested into Neurotar by two angel investors during 2010-2012. The investment was used to build up Neurotar’s infrastructure and provide working capital.
The focus of 2012 Symposium was on CNS. The feedback was overwhelmingly positive. In response to the requests of this year’s attendees, next year’s topics will include data analysis and skin imaging.
During a three-day trip, Neurotar’s Katja Karelina and Leonard Khirug visited five pharma and biotech companies in the Zurich area and in Lausanne, and met many more Swiss companies at the Swiss-Scandinavian Bio-Business Seminar. Neurotar also held a presentation at the latter event.